期刊论文详细信息
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 卷:56
Novel Baroreflex Activation Therapy in Resistant Hypertension Results of a European Multi-Center Feasibility Study
Article
Scheffers, Ingrid J. M.2  Kroon, Abraham A.2  Schmidli, Juerg3  Jordan, Jens4,5,6  Tordoir, Jan J. M.2  Mohaupt, Markus G.3  Luft, Friedrich C.5,6  Haller, Hermann4  Menne, Jan4  Engeli, Stefan5,6  Ceral, Jiri7  Eckert, Siegfried8  Erglis, Andrejs9  Narkiewicz, Krzysztof10  Philipp, Thomas11  de Leeuw, Peter W.1,2 
[1] Univ Hosp Maastricht, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands
[2] CARIM, Maastricht, Netherlands
[3] Univ Hosp Bern, Inselspital, CH-3010 Bern, Switzerland
[4] Hannover Med Sch, D-3000 Hannover, Germany
[5] Charite, Berlin, Germany
[6] HELIOS Klin, Berlin, Germany
[7] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic
[8] Heart & Diabet Ctr N Rhine Westphalia, Bad Oeynhausen, Germany
[9] Latvian Ctr Cardiol, Riga, Latvia
[10] Med Univ Gdansk, Gdansk, Poland
[11] Univ Hosp Essen, Essen, Germany
关键词: baroreflex;    device;    feasibility;    hypertension;    treatment;   
DOI  :  10.1016/j.jacc.2010.03.089
来源: Elsevier
PDF
【 摘 要 】

Objectives This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. Background Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. Methods Forty-five subjects with systolic blood pressure >= 160 mm Hg or diastolic >= 90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An external programmer was used to optimize and individualize efficacy. Results Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. Conclusions The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial. (J Am Coll Cardiol 2010;56:1254-8) (C) 2010 by the American College of Cardiology Foundation

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jacc_2010_03_089.pdf 445KB PDF download
  文献评价指标  
  下载次数:3次 浏览次数:0次